Not available
Quote | Clariant AG ADR (OTCMKTS:CLZNY)
Last: | $13.52 |
---|---|
Change Percent: | 0.0% |
Open: | $13.52 |
Close: | $13.52 |
High: | $13.52 |
Low: | $13.52 |
Volume: | 791 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
News | Clariant AG ADR (OTCMKTS:CLZNY)
Gevo Inc. (GEVO) is expected to report $-0.05 for Q4 2023 Harvard Bioscience Inc. (HBIO) is expected to report $0.03 for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 DFI Retail Group Holdings Limited ADR (DFIHY) is expected to report for quarter end 2...
Clariant AG ADR (CLZNY) is expected to report for Q4 2023
Message Board Posts | Clariant AG ADR (OTCMKTS:CLZNY)
Subject | By | Source | When |
---|---|---|---|
Govind: A new market assessment report on | Govind | investorshangout | 10/10/2019 7:27:45 AM |
Govind: A new market assessment report on | Govind | investorshangout | 09/13/2019 6:51:06 AM |
Emylers: CLZNY Financials 07/16/2014 12:38:22 Clariant AG Period Ending Total Revenue Cost of Revenu | Emylers | investorshangout | 07/16/2014 5:38:18 PM |
chartguy89: CLZNY 21.38 Stock Charts $CLZNY 1 Month Chart | chartguy89 | investorshangout | 03/06/2014 5:20:59 PM |
chartguy89: CLZNY Stock Charts Last: +0.13 Monday, February 24, 2014 at 6:59:56 PM $CLZNY 1 | chartguy89 | investorshangout | 02/25/2014 12:00:07 AM |
News, Short Squeeze, Breakout and More Instantly...
Clariant AG ADR Company Name:
CLZNY Stock Symbol:
OTCMKTS Market:
Gevo Inc. (GEVO) is expected to report $-0.05 for Q4 2023 Harvard Bioscience Inc. (HBIO) is expected to report $0.03 for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 DFI Retail Group Holdings Limited ADR (DFIHY) is expected to report for quarter end 2...
Clariant AG ADR (CLZNY) is expected to report for Q4 2023
NEW YORK, June 19, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Carvana Co. (NYSE: CVNA), Enochian Biosciences, Inc. (NASDAQ: ENOB), Corcept Therapeutics, Inc. (NASDAQ: CORT), and Cla...